Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
In this peer-to-peer discussion, Petros Grivas, MD, PhD, of the Cleveland Clinic in Cleveland, Ohio, and Phillip L. Palmbos, MD, PhD, of the University of Michigan in Ann Arbor, Michigan, examine the role of neoadjuvant chemotherapy in bladder cancer, weighing the various trial data that guide these treatment decisions, with considerations for patient comorbidities.
Financial Disclosure:Dr. Grivas is a consultant for Genentech.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
